Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Income (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Operating Income data on record, last reported at $60.8 million in Q4 2025.

  • For Q4 2025, Operating Income rose 59.42% year-over-year to $60.8 million; the TTM value through Dec 2025 reached $179.6 million, up 5.73%, while the annual FY2025 figure was $179.6 million, 5.73% up from the prior year.
  • Operating Income reached $60.8 million in Q4 2025 per COLL's latest filing, down from $62.1 million in the prior quarter.
  • Across five years, Operating Income topped out at $62.1 million in Q3 2025 and bottomed at -$34.1 million in Q4 2021.
  • Average Operating Income over 5 years is $28.4 million, with a median of $29.7 million recorded in 2023.
  • Peak YoY movement for Operating Income: crashed 327.54% in 2021, then surged 424.69% in 2023.
  • A 5-year view of Operating Income shows it stood at -$34.1 million in 2021, then skyrocketed by 134.46% to $11.8 million in 2022, then soared by 424.69% to $61.7 million in 2023, then crashed by 38.22% to $38.1 million in 2024, then surged by 59.42% to $60.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were $60.8 million in Q4 2025, $62.1 million in Q3 2025, and $35.1 million in Q2 2025.